A Food and Drug Administration (FDA) advisory panel has given a thumbs-up recommendation to Novo Nordisk’s type 2 diabetes drug liraglutide for the treatment of chronic obesity in patients with at least one weight-related health issue, such as hypertension or pre-diabetes. Liraglutide, known commercially as Victoza, would be sold under the label Saxenda for the obesity indication if it is approved by the FDA. The agency is not required to follow the recommendations of its advisory panels, but it usually does. The positive recommendation was based on a clinical trial in which patients were given 3 mg of liraglutide. About ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.